The End of the 10-Year Wait: How Saliva and Blood Tests Are Transforming Endometriosis Diagnosis

For decades, women suffering from debilitating pelvic pain have faced a grueling medical gauntlet: an average seven-to-ten-year wait for an endometriosis diagnosis. Because the disease's symptoms mimic other gynecological and gastrointestinal issues, patients are frequently dismissed, misdiagnosed, or told their pain is a normal part of menstruation.[1][2]

Until now, the only way to definitively prove the presence of endometriosis was through a laparoscopy—an invasive surgical procedure requiring general anesthesia, abdominal incisions, and a tissue biopsy. But in 2026, that century-old paradigm is finally collapsing.[3][8]

A new wave of non-invasive saliva and blood tests has reached the clinic, promising to diagnose the condition in weeks rather than years. By shifting endometriosis from a surgical diagnosis to a molecular one, medicine is finally treating the disease with the urgency and precision it demands.[1][3][8]

The stakes for this shift are massive. Endometriosis affects roughly one in ten women of reproductive age, translating to an estimated 200 million people worldwide. The condition occurs when tissue similar to the lining of the uterus grows outside the uterine cavity, adhering to the ovaries, fallopian tubes, and even the bowel.[3]

This ectopic tissue responds to monthly hormonal fluctuations, bleeding and creating severe inflammation and scar tissue. The resulting symptoms include chronic pelvic pain, painful intercourse, heavy periods, and, in up to 50% of cases, unexplained infertility.[2][4]

Conventional imaging, such as ultrasound and MRI, can sometimes detect large endometriotic cysts, but they frequently miss the superficial lesions that cause immense pain in early-stage disease. This imaging blind spot is what historically forced patients onto the operating table just to get an answer.[7][8]

The most prominent leap forward in non-invasive testing is the Ziwig Endotest, a saliva-based diagnostic developed by a French medical technology team. Rather than looking for the physical lesions, the test looks for the genetic signals the lesions leave behind.[4]

The Ziwig Endotest analyzes 109 specific salivary microRNAs—tiny, non-coding RNA molecules that regulate gene expression and are altered by the presence of the disease. By processing the saliva sample through next-generation sequencing and a proprietary artificial intelligence model, the test identifies the unique microRNA signature of endometriosis.[1][4]

The clinical data backing this approach is unprecedented. In a landmark multicenter study published in NEJM Evidence in late 2025, the saliva test demonstrated a 96.6% overall accuracy and a 97.3% sensitivity in a trial of nearly 1,000 symptomatic women.[1]

The test maintained its high performance regardless of whether the patient was taking hormonal birth control or pain medication. Recognizing the breakthrough, the French government recently approved the test for reimbursement under an early access program, making it available by prescription in 100 hospitals across the country.[1]

While Europe pioneers saliva testing, the United States and Australia are advancing highly accurate blood tests. At the Endocrine Society Annual Meeting in June 2026, HerAnova Lifesciences presented clinical validation data for HerResolve, a first-of-its-kind multi-omic blood test.[5]

Rather than relying on a single type of marker, HerResolve integrates data from three microRNAs, three protein biomarkers, and a steroid hormone. Analyzed alongside the patient's age and BMI using a machine-learning algorithm, the blood test achieved a 94.4% accuracy rate. It is currently rolling out at select IVF and reproductive medicine centers in the U.S.[5]

Other biotech firms are also entering the fray. DotLab's DotEndo utilizes a blood-based microRNA panel to provide a clear positive or negative result, specifically targeting the diagnostic gap for women experiencing unexplained infertility. Meanwhile, Australia's Proteomics International is launching PromarkerEndo, a test that measures a panel of ten protein biomarkers to detect the disease.[3][6]

For patients, a positive non-invasive test fundamentally changes the trajectory of care. Instead of waiting years for surgical validation, doctors can immediately prescribe targeted medical therapies, such as GnRH antagonists or specialized progestins, to suppress the disease and manage pain.[3][7]

The tests also offer a critical lifeline for fertility. Because endometriosis is a leading cause of infertility, rapid diagnosis allows patients to adjust their conception strategies—such as moving directly to IVF or freezing eggs—without losing precious time to surgical recovery or diagnostic limbo.[2][7]

Despite the immense promise, gynecological surgeons caution that biomarkers are a triage tool, not a complete replacement for surgical intervention. While a blood or saliva test can confirm the presence of endometriosis, it cannot reveal the anatomical location, depth, or stage of the lesions.[7][8]

For patients with deep infiltrating endometriosis—where the tissue has invaded the bowel, bladder, or ureters—laparoscopic excision surgery remains absolutely essential to remove the disease and restore normal pelvic anatomy. The tests cannot cure the disease; they only identify it.[7]

The immediate hurdle facing these innovations is accessibility. While early adopters and specialized clinics are offering the tests, widespread insurance coverage remains patchy outside of France's early access program. In the U.S. and other markets, patients often face out-of-pocket costs while companies pursue full FDA clearance and lobby for standard-of-care reimbursement.[1][8]

Nevertheless, the arrival of highly accurate liquid biopsies marks the beginning of the end for the endometriosis diagnostic odyssey. By validating women's pain with objective molecular data, these tests are dismantling a legacy of medical dismissal and opening a new era of proactive, personalized care.[6][8]